{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T09:29:39Z","timestamp":1784366979816,"version":"3.55.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.ejmech.2024.116602","type":"journal-article","created":{"date-parts":[[2024,6,22]],"date-time":"2024-06-22T22:27:56Z","timestamp":1719095276000},"page":"116602","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Synthesis and evaluation of neuroactive steroids with novel pharmacophore at C-21 let identify a compound with advantageous PK profile and higher EC50 and Emax as PAM on GABAA receptor"],"prefix":"10.1016","volume":"276","author":[{"given":"Mingxu","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hengwei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunmei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haibo","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanglin","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijie","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingjie","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingwei","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2024.116602_bib1","first-page":"27","article-title":"Natural and synthetic neuroactive steroid modulators of GABA(A) and NMDA receptors","volume":"49","author":"Martinez-Botella","year":"2014","journal-title":"Annu. Rep. Med. Chem."},{"issue":"4753","key":"10.1016\/j.ejmech.2024.116602_bib2","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1126\/science.2422758","article-title":"Steroid hormone metabolites are barbiturate-like modulators of the GABA receptor","volume":"232","author":"Majewska","year":"1986","journal-title":"Science"},{"issue":"7118","key":"10.1016\/j.ejmech.2024.116602_bib3","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/nature05324","article-title":"Endogenousneurosteroids regulate GABAA receptors through two discrete transmembrane sites","volume":"444","author":"Hosie","year":"2006","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.ejmech.2024.116602_bib4","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.pharmthera.2007.03.011","article-title":"Neurosteroid binding sites in GABA(A) receptors","volume":"116","author":"Hosie","year":"2007","journal-title":"Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.ejmech.2024.116602_bib5","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.coph.2005.10.003","article-title":"GABA-based therapeutic approaches: GABAA receptor subtype functions","volume":"6","author":"Rudolph","year":"2006","journal-title":"Curr. Opin. Pharmacol."},{"issue":"5","key":"10.1016\/j.ejmech.2024.116602_bib6","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1124\/mol.51.5.833","article-title":"Two tyrosine residues on the alpha subunit are crucial for benzodiazepine binding and allosteric modulation of gamma-aminobutyric acidA receptors","volume":"51","author":"Amin","year":"1997","journal-title":"Mol. Pharmacol."},{"issue":"3","key":"10.1016\/j.ejmech.2024.116602_bib7","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/S0021-9258(18)45961-3","article-title":"A single histidine in GABAA receptors is essential for benzodiazepine agonist binding","volume":"267","author":"Wieland","year":"1992","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.ejmech.2024.116602_bib8","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1042\/bst0320553","article-title":"Differentiating the role of gammaaminobutyric acid type A (GABAA) receptor subtypes","volume":"32","author":"Wafford","year":"2004","journal-title":"Biochem. Soc. Trans."},{"issue":"Suppl 6","key":"10.1016\/j.ejmech.2024.116602_bib9","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/epi.12289","article-title":"Neuroactive steroids for the treatment of status epilepticus","volume":"6","author":"Rogawski","year":"2013","journal-title":"Epilepsia"},{"issue":"2","key":"10.1016\/j.ejmech.2024.116602_bib10","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.neuron.2008.06.019","article-title":"GABAA-R plasticity during pregnancy: relevance to postpartum depression","volume":"59","author":"Maguire","year":"2008","journal-title":"Neuron"},{"issue":"9","key":"10.1016\/j.ejmech.2024.116602_bib11","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1523\/JNEUROSCI.4945-06.2007","article-title":"Neurosteroid synthesis-mediated regulation of GABA(A) receptors:relevance to the ovarian cycle and stress","volume":"27","author":"Maguire","year":"2007","journal-title":"J. Neurosci."},{"issue":"6","key":"10.1016\/j.ejmech.2024.116602_bib12","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/nn1469","article-title":"Ovarian cycle-linkedchanges in GABA(A) receptors mediating tonic inhibition alter seizure susceptibility and anxiety","volume":"8","author":"Maguire","year":"2005","journal-title":"Nat. Neurosci."},{"issue":"19","key":"10.1016\/j.ejmech.2024.116602_bib13","doi-asserted-by":"crossref","first-page":"7132","DOI":"10.1073\/pnas.1403285111","article-title":"Neurosteroids promote phosphorylation and membrane insertion of extrasynaptic GABAA receptors","volume":"111","author":"Abramian","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"2","key":"10.1016\/j.ejmech.2024.116602_bib14","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1177\/1060028019873320","article-title":"Brexanolone (Zulresso): Finally, an FDA-approved treatment for postpartum depression","volume":"54","author":"Powell","year":"2020","journal-title":"Ann. Pharmacother."},{"issue":"2","key":"10.1016\/j.ejmech.2024.116602_bib15","doi-asserted-by":"crossref","DOI":"10.1002\/hup.2576","article-title":"Open-label, proof-of-concept study of brexanolone in the treatment of severe postpartum depression","volume":"32","author":"Kanes","year":"2017","journal-title":"Hum. Psychopharmacol."},{"issue":"5","key":"10.1016\/j.ejmech.2024.116602_bib16","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/0022-4731(75)90041-2","article-title":"Structure-activity relationships in steroidal anaesthetics","volume":"6","author":"Phillipps","year":"1975","journal-title":"J. Steroid Biochem."},{"issue":"3","key":"10.1016\/j.ejmech.2024.116602_bib17","first-page":"1284","article-title":"Characterization of the anticonvulsant properties of ganaxolone (CCD 1042; 3alphahydroxy-3beta-methyl-5alpha-pregnan-20-one), a selective, high-affinity, steroid modulator of the gamma-aminobutyric acid(A) receptor","volume":"280","author":"Carter","year":"1997","journal-title":"J. Pharmacol. Exp. Therapeut."},{"issue":"1\u20132","key":"10.1016\/j.ejmech.2024.116602_bib18","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.brainres.2005.01.022","article-title":"Intracellular oxidation of allopregnanolone by human brain type 10 17beta-hydroxysteroid dehydrogenase","volume":"1040","author":"He","year":"2005","journal-title":"Brain Res."},{"key":"10.1016\/j.ejmech.2024.116602_bib19","doi-asserted-by":"crossref","first-page":"4573","DOI":"10.1021\/ja00301a048","article-title":"Methylaluminum bis(2,6-di-tert-butyl-4-alkylphenoxide). A new reagent for obtaining unusual equatorial and anti-Cram selectivity in carbonyl alkylation","volume":"107","author":"Maruoka","year":"1985","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2024.116602_bib20","unstructured":"G. Martinez-Botella, B.L. Harrison, A.J. Robichaud, et al., 19-Nor-C3,3-disubstituted C21-N-Pyrazolyl Steroids as GABA Receptor Modulators and Their Preparation. WO2014169833."},{"key":"10.1016\/j.ejmech.2024.116602_bib21","unstructured":"G. Martinez-Botella, B.L. Harrison, A.J. Robichaud, et al., Neuroactive Steroids in Treatment of CNS-Related Diseases and Their Preparation. WO2015180679."},{"key":"10.1016\/j.ejmech.2024.116602_bib26","unstructured":"Y.T. Song, H. Li, Tetrazolone Substituted Steroids and Use Thereof. WO2020150210."},{"issue":"3","key":"10.1016\/j.ejmech.2024.116602_bib22","first-page":"747","article-title":"Phenylquinolines PK 8165 and PK 9084 allosterically modulate [35S]t-butylbicyclophosphorothionate binding to a chloride ionophore in rat brain via a novel Ro5 4864 binding site","volume":"240","author":"Gee","year":"1987","journal-title":"J. Pharmacol. Exp. Therapeut."},{"issue":"8","key":"10.1016\/j.ejmech.2024.116602_bib23","doi-asserted-by":"crossref","first-page":"3500","DOI":"10.1021\/acs.jmedchem.5b00032","article-title":"Neuroactive steroids. 1. Positive allosteric modulatorsof the (\u03b3-Aminobutyric Acid)A receptor: structure-activity relationships of heterocyclic substitution at C-21","volume":"58","author":"Martinez-Botella","year":"2015","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2024.116602_bib24","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.pharmthera.2007.03.004","article-title":"Mechanisms of neurosteroid interactions with GABA(A) receptors","volume":"116","author":"Akk","year":"2007","journal-title":"Pharmacol. Ther."},{"issue":"18","key":"10.1016\/j.ejmech.2024.116602_bib25","doi-asserted-by":"crossref","first-page":"7810","DOI":"10.1021\/acs.jmedchem.7b00846","article-title":"Neuroactive steroids. 2. 3\u03b1-Hydroxy-3\u03b2-methyl-21-(4-cyano-1H-pyrazol-1'-yl)-19-nor-5\u03b2-pregnan-20-one (SAGE-217): a clinical next generation neuroactive steroid positive allosteric modulator of the (\u03b3-Aminobutyric Acid)A receptor","volume":"60","author":"Martinez","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116602_bib27","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.2147\/NDT.S164307","article-title":"Valium without dependence? Individual GABAA receptor subtype contribution toward benzodiazepine addiction, tolerance, and therapeutic effects","volume":"14","author":"Cheng","year":"2018","journal-title":"Neuropsychiatric Dis. Treat."},{"issue":"1","key":"10.1016\/j.ejmech.2024.116602_bib28","doi-asserted-by":"crossref","first-page":"5091","DOI":"10.1038\/s41467-023-40800-1","article-title":"Structural insights into opposing actions of neurosteroids on GABAA receptors","volume":"14","author":"Legesse","year":"2023","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.ejmech.2024.116602_bib29","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1124\/mol.108.048520","article-title":"Mutations of the GABA-A receptor alpha1 subunit M1 domain reveal unexpected complexity for modulation by neuroactive steroids","volume":"74","author":"Akk","year":"2008","journal-title":"Mol. Pharmacol."},{"issue":"4","key":"10.1016\/j.ejmech.2024.116602_bib30","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1124\/mol.108.053629","article-title":"Steroid interaction with a single potentiating site is sufficient to modulate GABA-A receptor function","volume":"75","author":"Bracamontes","year":"2009","journal-title":"Mol. Pharmacol."},{"issue":"3","key":"10.1016\/j.ejmech.2024.116602_bib31","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1021\/jm2014925","article-title":"Neurosteroid analogues. 17. Inverted binding orientations of androsterone enantiomers at the steroid potentiation site on \u03b3-aminobutyric acid type A receptors","volume":"55","author":"Krishnan","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116602_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2020.108333","article-title":"Preclinical characterization of zuranolone (SAGE-217), a selective neuroactive steroid GABAA receptor positive allosteric modulator","volume":"181","author":"Althaus","year":"2020","journal-title":"Neuropharmacology"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523424004823?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523424004823?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T16:47:25Z","timestamp":1730738845000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523424004823"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":32,"alternative-id":["S0223523424004823"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2024.116602","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Synthesis and evaluation of neuroactive steroids with novel pharmacophore at C-21 let identify a compound with advantageous PK profile and higher EC50 and Emax as PAM on GABAA receptor","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2024.116602","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"116602"}}